C1 inhibitor deficiency in hereditary angioneurotic oedema

J. Krámer, K. Madalinski

Research output: Contribution to journalArticle

Abstract

Hereditary angioneurotic oedema (HAE) is an autosomal dominant disorder, due to the deficiency of C1-inhibitor, a 105-kd glycoprotein. The two biochemical and clinical forms of HAE are characterized by very low 5-30% of functionally active C1-inhibitor levels, if compared to healthy individuals. Fibroblasts from healthy persons and HAE patients synthesize C1-inhibitor in amount parallel to concentration in the sera: in type I HAE fibroblasts produce only 20%; while in type II HAE 100% of normal value. The C1-inhibitor synthesis can be increased by IFN-γ at pretranslational level. These-data were confirmed with cultures of fibroblasts from patients treated in the Child Health Center (up to 21-fold increase of C1-inhibitor synthesis). In several cases of type II HAE, the mutant, dysfunctional C1-inhibitor was released from the intracellular matrix of fibroblasts with a lower rate than normal. The secreted protein reacted with activated C1s. Studies of fibroblasts derived from a patient with deletion of exon VII allowed us to suggest a transinhibitory effect of the mutant gene product resulting in the lower than expected C1-inhibitor levels (50%) in the heterozygous persons.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalPolish Journal of Immunology
Volume19
Issue number1
Publication statusPublished - 1994

Fingerprint

Hereditary Angioedemas
Fibroblasts
Exons
Glycoproteins
Reference Values
Serum

ASJC Scopus subject areas

  • Immunology

Cite this

C1 inhibitor deficiency in hereditary angioneurotic oedema. / Krámer, J.; Madalinski, K.

In: Polish Journal of Immunology, Vol. 19, No. 1, 1994, p. 61-67.

Research output: Contribution to journalArticle

@article{97520ca5d624442c9e655b62f3601630,
title = "C1 inhibitor deficiency in hereditary angioneurotic oedema",
abstract = "Hereditary angioneurotic oedema (HAE) is an autosomal dominant disorder, due to the deficiency of C1-inhibitor, a 105-kd glycoprotein. The two biochemical and clinical forms of HAE are characterized by very low 5-30{\%} of functionally active C1-inhibitor levels, if compared to healthy individuals. Fibroblasts from healthy persons and HAE patients synthesize C1-inhibitor in amount parallel to concentration in the sera: in type I HAE fibroblasts produce only 20{\%}; while in type II HAE 100{\%} of normal value. The C1-inhibitor synthesis can be increased by IFN-γ at pretranslational level. These-data were confirmed with cultures of fibroblasts from patients treated in the Child Health Center (up to 21-fold increase of C1-inhibitor synthesis). In several cases of type II HAE, the mutant, dysfunctional C1-inhibitor was released from the intracellular matrix of fibroblasts with a lower rate than normal. The secreted protein reacted with activated C1s. Studies of fibroblasts derived from a patient with deletion of exon VII allowed us to suggest a transinhibitory effect of the mutant gene product resulting in the lower than expected C1-inhibitor levels (50{\%}) in the heterozygous persons.",
author = "J. Kr{\'a}mer and K. Madalinski",
year = "1994",
language = "English",
volume = "19",
pages = "61--67",
journal = "Central-European Journal of Immunology",
issn = "1426-3912",
publisher = "Termedia Publishing House Ltd.",
number = "1",

}

TY - JOUR

T1 - C1 inhibitor deficiency in hereditary angioneurotic oedema

AU - Krámer, J.

AU - Madalinski, K.

PY - 1994

Y1 - 1994

N2 - Hereditary angioneurotic oedema (HAE) is an autosomal dominant disorder, due to the deficiency of C1-inhibitor, a 105-kd glycoprotein. The two biochemical and clinical forms of HAE are characterized by very low 5-30% of functionally active C1-inhibitor levels, if compared to healthy individuals. Fibroblasts from healthy persons and HAE patients synthesize C1-inhibitor in amount parallel to concentration in the sera: in type I HAE fibroblasts produce only 20%; while in type II HAE 100% of normal value. The C1-inhibitor synthesis can be increased by IFN-γ at pretranslational level. These-data were confirmed with cultures of fibroblasts from patients treated in the Child Health Center (up to 21-fold increase of C1-inhibitor synthesis). In several cases of type II HAE, the mutant, dysfunctional C1-inhibitor was released from the intracellular matrix of fibroblasts with a lower rate than normal. The secreted protein reacted with activated C1s. Studies of fibroblasts derived from a patient with deletion of exon VII allowed us to suggest a transinhibitory effect of the mutant gene product resulting in the lower than expected C1-inhibitor levels (50%) in the heterozygous persons.

AB - Hereditary angioneurotic oedema (HAE) is an autosomal dominant disorder, due to the deficiency of C1-inhibitor, a 105-kd glycoprotein. The two biochemical and clinical forms of HAE are characterized by very low 5-30% of functionally active C1-inhibitor levels, if compared to healthy individuals. Fibroblasts from healthy persons and HAE patients synthesize C1-inhibitor in amount parallel to concentration in the sera: in type I HAE fibroblasts produce only 20%; while in type II HAE 100% of normal value. The C1-inhibitor synthesis can be increased by IFN-γ at pretranslational level. These-data were confirmed with cultures of fibroblasts from patients treated in the Child Health Center (up to 21-fold increase of C1-inhibitor synthesis). In several cases of type II HAE, the mutant, dysfunctional C1-inhibitor was released from the intracellular matrix of fibroblasts with a lower rate than normal. The secreted protein reacted with activated C1s. Studies of fibroblasts derived from a patient with deletion of exon VII allowed us to suggest a transinhibitory effect of the mutant gene product resulting in the lower than expected C1-inhibitor levels (50%) in the heterozygous persons.

UR - http://www.scopus.com/inward/record.url?scp=0028137005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028137005&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 61

EP - 67

JO - Central-European Journal of Immunology

JF - Central-European Journal of Immunology

SN - 1426-3912

IS - 1

ER -